Daiichi Sankyo

News

AZ, Daiichi get EU okay for breast cancer drug Datroway

AstraZeneca and Daiichi Sankyo have claimed approval from the European Commission for Datroway, their TROP2-directed ADC for breast cancer.

News

Enhertu extends survival in advanced gastric cancer

Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.

News

Ono poised to join Daiichi in TGCT market after FDA nod

Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT).

News

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Roche gets the first FDA approval for a diagnostic test for HER2-ultralow breast cancer, now on the label of AstraZeneca and Daiichi Sankyo's Enhertu.

News

Enhertu gets first okay for HER2-ultralow breast cancer

Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.

News

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate for breast cancer - TROP2-directed Datroway.

AZ, Daiichi get EU okay for breast cancer drug Datroway

Enhertu extends survival in advanced gastric cancer

Ono poised to join Daiichi in TGCT market after FDA nod

Boost to Enhertu's prospects as FDA clears Roche diagnostic

Enhertu gets first okay for HER2-ultralow breast cancer

AZ, Daiichi get FDA nod for Dato-DXd in breast cancer

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Daiichi Sankyo

Editor's Picks